Department of Organic Chemistry, University of Debrecen, POB 20, H-4010 Debrecen, Hungary.
Carbohydr Res. 2011 Sep 6;346(12):1427-38. doi: 10.1016/j.carres.2011.03.004. Epub 2011 Mar 8.
5-(O-Perbenzoylated-β-D-glucopyranosyl)tetrazole was obtained from O-perbenzoylated-β-D-glucopyranosyl cyanide by Bu(3)SnN(3) or Me(3)SiN(3)-Bu(2)SnO. This tetrazole was transformed into 5-ethynyl- as well as 5-chloromethyl-2-(O-perbenzoylated-β-D-glucopyranosyl)-1,3,4-oxadiazoles by acylation with propiolic acid-DCC or chloroacetyl chloride, respectively. The chloromethyl oxadiazole gave the corresponding azidomethyl derivative on treatment with NaN(3). These compounds were reacted with several alkynes and azides under Cu(I) catalysed cycloaddition conditions to give, after removal of the protecting groups by the Zemplén protocol, β-D-glucopyranosyl-1,3,4-oxadiazolyl-1,2,3-triazole, β-D-glucopyranosyl-1,2,3-triazolyl-1,3,4-oxadiazole, and β-D-glucopyranosyl-1,3,4-oxadiazolylmethyl-1,2,3-triazole type compounds. 5-Phenyltetrazole was also transformed under the above conditions into a series of aryl-1,3,4-oxadiazolyl-1,2,3-triazoles, aryl-1,2,3-triazolyl-1,3,4-oxadiazoles, and aryl-1,3,4-oxadiazolylmethyl-1,2,3-triazoles. The new compounds were assayed against rabbit muscle glycogen phosphorylase b and the best inhibitors had inhibition constants in the upper micromolar range (2-phenyl-5-[1-(β-D-glucopyranosyl)-1,2,3-triazol-4-yl]-1,3,4-oxadiazole 36: K(i)=854μM, 2-(β-D-glucopyranosyl)-5-[1-(naphthalen-2-yl)-1,2,3-triazol-4-yl]-1,3,4-oxadiazole 47: K(i)=745μM).
5-(O-全苯甲酰基-β-D-吡喃葡萄糖基)四唑可由 O-全苯甲酰基-β-D-吡喃葡萄糖基氰化物经 Bu(3)SnN(3)或 Me(3)SiN(3)-Bu(2)SnO 得到。该四唑经丙炔酸-DCC 或氯乙酰氯酰化分别转化为 5-乙炔基-和 5-氯甲基-2-(O-全苯甲酰基-β-D-吡喃葡萄糖基)-1,3,4-恶二唑。氯甲基恶二唑经NaN(3)处理得到相应的叠氮甲基衍生物。这些化合物在 Cu(I)催化的环加成条件下与几种炔烃和叠氮化物反应,然后通过 Zemplén 方案去除保护基团,得到β-D-吡喃葡萄糖基-1,3,4-恶二唑基-1,2,3-三唑、β-D-吡喃葡萄糖基-1,2,3-三唑基-1,3,4-恶二唑和β-D-吡喃葡萄糖基-1,3,4-恶二唑基甲基-1,2,3-三唑类化合物。5-苯基四唑也在上述条件下转化为一系列芳基-1,3,4-恶二唑基-1,2,3-三唑、芳基-1,2,3-三唑基-1,3,4-恶二唑和芳基-1,3,4-恶二唑基甲基-1,2,3-三唑类化合物。新化合物在兔肌肉糖原磷酸化酶 b 上进行了测定,最佳抑制剂的抑制常数在微摩尔范围内(2-苯基-5-[1-(β-D-吡喃葡萄糖基)-1,2,3-三唑-4-基]-1,3,4-恶二唑 36:K(i)=854μM,2-(β-D-吡喃葡萄糖基)-5-[1-(萘-2-基)-1,2,3-三唑-4-基]-1,3,4-恶二唑 47:K(i)=745μM)。